DNAJB9

Mutation & survival
SurvivalMutationKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, DNAJB9 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated DNAJB9 data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher DNAJB9 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DNAJB9 expression acts as an unfavorable survival marker.

HNSC, LUSC, and UCEC are the cancer types where DNAJB9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
HNSCOSMedianIII,IV0.0870.746<.00148view →
LUSCOSMedianAll0.1720.776.00224view →
UCECOSMedianIV0.2310.592.0366view →
Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

DNAJB9–HNSC (OS)

Kaplan–Meier survival curve for DNAJB9 mutant vs wild-type samples in HNSC.

Open the HNSC breakdown →

Exploration